Immunomodulator Treatment Options in Septic and ARDS COVID-19 Patients

Author(s): Mary Lawanson-Nichols, MSN, CNS, NP, CCRN, FCNS; Jacob Miller, DNP, MBA, NP, CNS, FAEN; Thomas Ahrens, PhD, RN, FAAN

CERP A 0.90

Expires Nov 05, 2025

Topics: COVID-19, Sepsis

Population: Adult

Role: Staff, APRN

This activity will NOT be recognized for ANCC and CA BRN accredited contact hours.

This activity will be recognized for Synergy CERPs hours for the education presented.

See Continuing Education Disclosure Statement for more information.

Added to Collection

Sponsor Logo

Activity Summary

Presentation discussing the ongoing issues of COVID-19 in the United States, the typical COVID patients being presented for hospitalization and the ICU, the current usage of immunomodulators (dexamethasone, baricitinib, tocilizumab, and vilobelimab) in the ICU patient, specific presentation of vilobelimab safety and efficacy data as well as a roundtable discussion among the authors.

Objectives

  • Understand how COVID-19 induces a hyperinflammatory state leading to host immune dysregulation in sepsis and ARDS
  • Identify the typical COVID-19 patients who progress from presentation to the ICU in need of invasive mechanical ventilation or ECMO.
  • Recommend treatment options based upon evidence-based clinical study outcomes for COVID-19 patients on IMV and ECMO

Continuing Education Disclosure Statement

Continuing Education Recognition Points (CERPs) are recognized by the AACN Certification Corporation, our credentialing arm, to encompass a wide spectrum of continuing education activities performed by nurses in high acuity and critical care and fulfill educational requirements for certification. Synergy CERP is a program exclusive to AACN for nurses wishing to recertify through AACN. State boards of nursing and other certification organizations may recognize CERPs as meeting CE Contact Hour requirements. We recommend consulting with the state board or credentialing organization before submitting CERPs to fulfill CEContact Hour requirements.